# FCR (NCT01723839)

> Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01723839
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Hackensack Meridian Health
- Conditions: Chronic Lymphocytic Leukemia (CLL)
- Interventions: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
- Enrollment: 21
- Primary outcome: Complete Response

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=fcr-nct01723839